These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34586105)

  • 1. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
    Lu Q; Huang H; Tang S; Wang Y; Yang DH
    Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    Salles G; Długosz-Danecka M; Ghesquières H; Jurczak W
    Expert Opin Biol Ther; 2021 Apr; 21(4):455-463. PubMed ID: 33554668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tafasitamab: First Approval.
    Hoy SM
    Drugs; 2020 Nov; 80(16):1731-1737. PubMed ID: 32946059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
    Belada D; Kopeckova K; Bergua Burgues JM; Stevens D; André M; Persona EP; Pichler P; Staber PB; Trneny M; Duell J; Waldron-Lynch M; Wagner S; Mukhopadhyay A; Dirnberger-Hertweck M; Burke JM; Nowakowski GS
    Blood; 2023 Oct; 142(16):1348-1358. PubMed ID: 37369099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    Davis JA; Shockley A; Glode AE
    J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Duell J; Maddocks KJ; González-Barca E; Jurczak W; Liberati AM; De Vos S; Nagy Z; Obr A; Gaidano G; Abrisqueta P; Kalakonda N; André M; Dreyling M; Menne T; Tournilhac O; Augustin M; Rosenwald A; Dirnberger-Hertweck M; Weirather J; Ambarkhane S; Salles G
    Haematologica; 2021 Sep; 106(9):2417-2426. PubMed ID: 34196165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Nedved A; Maddocks K; Nowakowski GS
    Oncologist; 2023 Mar; 28(3):199-207. PubMed ID: 36648324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
    Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.
    Abdulhaq H; Hwang A; Mahmood O
    Onco Targets Ther; 2023; 16():617-629. PubMed ID: 37492075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
    Pirosa MC; Stathis A; Zucca E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2309701. PubMed ID: 38299612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of tafasitamab in diffuse large B-cell lymphoma.
    Düll J; Topp M; Salles G
    Ther Adv Hematol; 2021; 12():20406207211027458. PubMed ID: 34285786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL.
    Tabbara N; Gaut D; Oliai C; Lewis T; de Vos S
    Leuk Res Rep; 2021; 16():100260. PubMed ID: 34354920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
    Her JH; Pretscher D; Patra-Kneuer M; Schanzer J; Cho SY; Hwang YK; Hoeres T; Boxhammer R; Heitmueller C; Wilhelm M; Steidl S; Endell J
    Cancer Immunol Immunother; 2022 Nov; 71(11):2829-2836. PubMed ID: 35348812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide in DLBCL: are we past the cell of origin?
    Goldfinger M; Cooper DL
    Clin Adv Hematol Oncol; 2021 May; 19(5):320-325. PubMed ID: 33989279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
    Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
    Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategies for patients with diffuse large B-cell lymphoma.
    Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
    Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.